Provided by Tiger Trade Technology Pte. Ltd.

COYA THERAPEUTICS INC

4.38
-0.1400-3.10%
Post-market: 4.380.00000.00%19:30 EDT
Volume:139.34K
Turnover:621.08K
Market Cap:102.70M
PE:-4.02
High:4.66
Open:4.59
Low:4.37
Close:4.52
52wk High:7.75
52wk Low:3.71
Shares:23.45M
Float Shares:17.54M
Volume Ratio:1.56
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0897
EPS(LYR):-1.2700
ROE:-60.54%
ROA:-32.27%
PB:2.37
PE(LYR):-3.45

Loading ...

Ram Selvaraju Reiterates Buy on Coya with Unchanged $18 Price Target as New COYA 303 Data Highlight Additional Upside Potential

TIPRANKS
·
Sep 09

Coya announces publication of preclinical study on effects of COYA 303

TIPRANKS
·
Sep 08

Coya Therapeutics Reports Preclinical Study Shows COYA 303 Combination Cuts Inflammation Markers in LPS Mouse Model

Reuters
·
Sep 08

Coya Therapeutics Posts September 2026 Investor Presentation on Neurodegeneration Pipeline

Reuters
·
Sep 01

BTIG Reaffirms Their Buy Rating on Coya Therapeutics, Inc. (COYA)

TIPRANKS
·
Aug 12

Acumen Pharmaceuticals Q2 Net Loss Widens, Misses Analyst Estimates

Reuters
·
Aug 12

Annexon Biosciences Q2 Net Loss Widens, Cash Runway Extended

Reuters
·
Aug 12

Coya Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Coya Therapeutics Posts Investor Presentation on Treg-Directed Combination Therapy for Neurodegenerative Diseases

Reuters
·
Aug 11

Coya Net Loss Widens to $6.64 Million in Q2 FY26; R&D Expense Rises to $5.03 Million

Reuters
·
Aug 11

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Aug 11

Coya Therapeutics Q2 EPS USD -0.28

THOMSON REUTERS
·
Aug 11

Coya Therapeutics Q2 Net Income USD -6.6 Million

THOMSON REUTERS
·
Aug 11

Coya Therapeutics Amends Filing to Name Mark Pavao to Audit Committee

Reuters
·
Aug 08

Coya Therapeutics Inc Expected to Post a Loss of 34 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI)

TIPRANKS
·
Jul 06

Coya Therapeutics Posts Investor Deck Outlining Treg-directed Combination Therapy Strategy for Neurodegenerative Diseases

Reuters
·
Jul 01

Coya Therapeutics Shareholders Approved Auditor Appointment for 2026 Fiscal Year

Reuters
·
Jun 26

H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA)

TIPRANKS
·
Jun 25

Coya Therapeutics presents ALSTARS Phase 2 trial design at ENCALS 2026 meeting

Reuters
·
Jun 18